Metabiomed Co Ltd

Metabiomed Co Ltd maintains a debt-to-equity ratio of 0.34, indicating a relatively conservative capital structure with a strong equity base. The company's liquidity position is characterized by a current ratio of 1.39, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -4,966,000,430 KRW, which may signal potential pressure on liquidity in the near term. In terms of profitability, Metabiomed's return on equity (ROE) is 8.84%, and its return on assets (ROA) is 5.89%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's operating income of 21,361,392,490 KRW and net income of 10,988,343,810 KRW reflect a healthy margin, although the gross profit margin of 52.1% is a critical factor in sustaining these returns. The company's revenue is distributed across three segments: Sutures, Dental, and Other. The Sutures segment provides surgical materials, including absorbable surgical sutures, while the Dental segment offers dental products and equipment. The Other segment includes orthopedic and other medical materials. The company's geographic exposure is primarily domestic, with a significant portion of its revenue derived from the Korean market. However, the company also operates in overseas markets, which may provide diversification benefits. Metabiomed's growth trajectory is supported by a positive outlook for the current fiscal year, with revenue expected to increase. The company's capital expenditure of -20,460,781,580 KRW indicates a significant investment in infrastructure and expansion, which may drive future growth. The company's operating cash flow of 19,832,876,150 KRW supports its operational activities and provides a buffer for future investments. The risk assessment for Metabiomed highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which may affect its ability to meet short-term obligations. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events and filings indicate that Metabiomed has maintained a stable financial position, with the last actual EPS at 438.00 KRW and the last actual revenue at 102,951,000,000 KRW. These figures align with the company's financial performance and suggest a consistent earnings pattern.